Predicting the Effectiveness of Therapy for Cancer Diseases

Abstract

Revealing of genetic features at patients on polymorphic marker С3435Т MDR1 gene allows to predict character of the pharmacological answer that gives the chance to raise efficiency and safety of application of medical products - a dose, frequency rate of introduction, an introduction way, replacement of medical products and real possibility of an individualization of pharmacotherapy at various oncological diseases. Definition of frequency of occurrence of genotypes among healthy donors and oncological patients with the diagnosis of breast cancer and non-Hodgkin's lymphoma is spent. It is shown, that frequency of occurrence of homozygous TT genotype at breast cancer and non-Hodgkin's lymphoma above, than occurrence of СС and СТ genotypes.